A recent study suggests that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end traditional lifestyle programs.
Research printed in a major health publication demonstrates that while obese individuals often shed substantial amounts of their total mass while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"People purchasing these medications should be aware of the danger of quick rebound weight gain when the medication concludes," warns lead investigator Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment weight within about one and a half years.
Comparing Treatments
The research, which reviewed 37 of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with other pills.
The team emphasize that people who lose weight through diet and exercise usually have a slower creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Fast Regain
Nutrition scientists propose the mechanism of the drugs accounts for the accelerated rebound.
The injections imitate a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than normal could lead to the system to produce less of its own natural GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' means hunger is uncontrolled, making binge eating much more probable."
A Lifelong Condition?
The NHS advise the jabs for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Many experts say that, considering the likelihood of relapse, the therapy might need to be ongoing.
This perspective is echoed by pharmaceutical companies, who state that the results "emphasize the persistent nature of excess weight," similar to managing diseases like diabetes.
User Testimonies
Individuals who have discontinued the medication explain a intense return of appetite.
"It felt as if a switch flipping and I was suddenly extremely hungry," described an individual.
This difficulty is worsened if individuals have not developed permanent dietary or behavioural modifications during therapy.
Growing Adoption
Figures indicate that a significant number of adults in the UK have used these injections in the past year, with interest continuing to grow.
- Adoption is more common among females than men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than public health services.
Ultimately, researchers caution that while GLP-1 drugs are effective agents for weight loss, they are not a permanent solution and maintained weight loss relies on combined behavioural management.